GlycoVaxyn AG

GlycoVaxyn is a Zurich based biotechnology company dedicated to the development of novel biotechnological methods for the production of glycoconjugates. The approach relies on a proprietary genetic system for the development and production of glycosylated therapeutic proteins used as medications or vaccines in simple bacterial cells (E. coli). GlycoVaxyn offers a solution to produce therapeutic glycoproteins faster and at lower costs. The company will develop its portfolio of novel conjugated vaccines and enter cooperations with life science companies.